Skip to content
News & Publications
News
Publications
Contact Us
About Us
History
Patents
Technology
Signaling Chain HOmoOLigomerization (“SCHOOL”) Platform Basics
Macrophage Modulation
Macrophage Imaging
Pipeline
Therapeutic Areas
Cancer
Autoimmune Diseases
Retinopathy
Atherosclerosis
Sepsis/ARDS & COVID
Other Inflammatory Diseases
Partners & Collaborators
Menu
Understanding Nature. Improving Life
Type and press enter to search
FDA grants Orphan Drug Designation to SignaBlok’s therapy for retinopathy of prematurity (ROP)
SignaBlok
>
News
>
FDA grants Orphan Drug Designation to SignaBlok’s therapy for retinopathy of prematurity (ROP)
SignaBlok
>
News
>
FDA grants Orphan Drug Designation to SignaBlok’s therapy for retinopathy of prematurity (ROP)
FDA grants Orphan Drug Designation to SignaBlok’s therapy for retinopathy of prematurity (ROP)
Post navigation
Previous Post
SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop TREM-1 therapy for the treatment of empyema
Next Post
SignaBlok to present favorable preclinical data on a first-in-class TREM-1 therapy for retinopathy of prematurity (ROP) at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting
Vera
View posts by Vera
Scroll to top
close ×
